ATTRACTION-2 [10] and JAVELIN Gastric 300 [11] trials did not show a strong link between efficacy of nivolumab/avelumab and tumor PD-L1 level; meanwhile, long-term analysis of KEYNOTE-061 trial found that second-line pembrolizumab prolonged OS only among patients with PD-L1-positive esophageal/EGJ AC [12, 13]. The gene discussed is CD274; the disease is neoplasm.